Recent developments include Q1 2026 earnings reporting revenue growth with higher costs, a CFO share sale prior to earnings release, and a partnership with LG Chem for Asia-Pacific commercialization of EXPAREL.

• Pacira reported Q1 2026 earnings with revenues rising year-over-year but higher costs impacting profitability [N1].
• The company's CFO sold 12,941 shares for $326,000 before the Q1 2026 earnings release [N2].
• Pacira held its Q1 2026 earnings call discussing financial results and business updates [N3].
• The company announced a partnership with LG Chem to commercialize EXPAREL in select Asia-Pacific markets, receiving a $2 million upfront payment and future royalties [N1].
• In Q4 2025, Pacira repurchased 2 million shares for $50 million under its share repurchase program [N5].

Pacira's portfolio of non-opioid pain management products addresses significant clinical needs, with EXPAREL and ZILRETTA offering differentiated therapies. The company's investment in gene therapy development through its HCAd vector platform could unlock new treatment opportunities. Manufacturing scale-up and efficiency improvements may enhance margins. Strategic partnerships expand geographic reach, and share repurchases demonstrate capital allocation focus. The company's strong liquidity supports ongoing R&D and commercialization efforts [S1][S2].

Pacira faces challenges from rising costs impacting profitability despite revenue growth. The company is exposed to global economic volatility, tariffs, and supply chain risks, particularly due to sourcing active pharmaceutical ingredients internationally. Legal proceedings and claims present ongoing uncertainties. Market competition and regulatory hurdles may affect product adoption and pipeline progress. Recent workforce reductions indicate operational adjustments that may impact execution. The company does not pay dividends, which may affect investor appeal [S1][S2][N1].

Pacira's moat is based on its proprietary pMVL drug delivery technology enabling long-acting local analgesics, a portfolio of complementary non-opioid pain management products, and its development pipeline including gene therapy candidates. Its manufacturing capabilities with large-scale batch suites and direct-to-end-user distribution model support operational efficiency. Strategic partnerships, such as with LG Chem for Asia-Pacific commercialization, and intellectual property from acquisitions contribute to competitive positioning. However, the company operates in a competitive pharmaceutical market with risks from regulatory, supply chain, and economic factors [S1][S2].

• Global Economic and Tariff Risks: Volatility in global economic conditions and tariffs may increase costs for raw materials and manufacturing, potentially impacting financial results.
• Supply Chain and Manufacturing Risks: Dependence on international suppliers for active pharmaceutical ingredients and manufacturing capacity expansion pose risks to product availability and cost structure.
• Legal and Regulatory Risks: Ongoing legal proceedings and regulatory requirements may result in liabilities or operational constraints.
• Market Competition and Adoption Risks: Competition in the pharmaceutical and pain management markets may limit product uptake and revenue growth.

• Pacira BioSciences, Inc. develops and commercializes non-opioid pain therapies including EXPAREL, ZILRETTA, and the iovera® system.
• EXPAREL is a long-acting local analgesic using proprietary pMVL drug delivery technology, indicated for postsurgical pain management in patients aged six years and older.
• ZILRETTA is an extended-release intra-articular injectable therapy for osteoarthritis knee pain, acquired through Flexion Therapeutics in 2021.
• The iovera® system is a handheld cryoanalgesia device acquired through MyoScience in 2019, sold directly to end users.
• The company is developing PCRX-201, a locally administered gene therapy for osteoarthritis of the knee, as part of its HCAd vector platform acquired through GQ Bio Therapeutics in 2025.
• Pacira operates manufacturing and R&D facilities primarily at its Science Center Campus in San Diego, California, with additional offices in New Jersey, California, and Germany.
• The company has a share repurchase program authorized up to $300 million, with 2 million shares repurchased in Q4 2025 for $50 million.
• As of March 31, 2026, Pacira had $144.3 million in cash and equivalents and $57.9 million in short-term investments, with a current ratio of 4.73 and a cash ratio of 1.86, indicating strong liquidity.
• For Q1 2026, Pacira reported net income of $2.9 million and basic and diluted EPS of $0.07 per share.
• Pacira's revenues for fiscal year 2021 were $541.5 million as per the latest available annual data.
• The company has a partnership with LG Chem to commercialize EXPAREL in select Asia-Pacific markets, receiving a $2 million upfront payment and future royalties.
• Pacira's manufacturing capacity has been enhanced by large-scale batch suites in San Diego and the UK, leading to a workforce reduction in 2025 to improve efficiency.
• Recent quarters have seen revenues rise year-over-year but with higher costs impacting earnings, as reported in Q1 2026.
• The CFO sold 12,941 shares for $326,000 prior to the Q1 2026 earnings release.
• Pacira's common stock is listed on Nasdaq under the ticker PCRX.
• The company does not pay dividends and intends to retain earnings for business development and expansion.
• Pacira faces risks related to global economic conditions, tariffs, and supply chain volatility, especially given its sourcing of active pharmaceutical ingredients from outside the U.S.
• The company is subject to ongoing legal proceedings and claims arising in the ordinary course of business.
• Pacira's product sales are drop-shipped directly to end-users with no inventory held by wholesalers.
• The company has invested in expanding sales, marketing, and manufacturing capacity for its key products.
• Pacira's board of directors increased to 10 members with the appointment of Dr. Samit Hirawat in January 2026.